BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019;83:1175-81. [PMID: 30927036 DOI: 10.1007/s00280-019-03820-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Meng Y, Huang X, Liu J, Chen J, Bu Z, Wu G, Xie W, Jeen F, Huang L, Tian C, Mo X, Tang W. A Novel Nomogram for Individually Predicting of Vascular Invasion in Gastric Cancer. Technol Cancer Res Treat 2021;20:15330338211004924. [PMID: 33929914 DOI: 10.1177/15330338211004924] [Reference Citation Analysis]
2 Niclauss N, Gütgemann I, Dohmen J, Kalff JC, Lingohr P. Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. Cancers (Basel) 2021;13:5660. [PMID: 34830815 DOI: 10.3390/cancers13225660] [Reference Citation Analysis]
3 Inagaki-Ohara K. Gastric Leptin and Tumorigenesis: Beyond Obesity. Int J Mol Sci 2019;20:E2622. [PMID: 31141984 DOI: 10.3390/ijms20112622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
4 Tong G, Li S, Lin L, He L, Wang L, Lv G, Zheng R, Wang S. Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study. Cancer Manag Res 2020;12:2481-9. [PMID: 32308484 DOI: 10.2147/CMAR.S239420] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Mori Y, Kataoka H, Ebi M, Adachi K, Yamaguchi Y, Hayashi N, Hirata Y, Sobue S, Ishihara R, Suzuki Y, Mizushima T, Inoue Y, Hasegawa I, Ono S, Hirano A, Kimura Y, Seno K, Ozeki K, Shimura T, Kubota E. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer 2021. [PMID: 34550548 DOI: 10.1007/s12029-021-00711-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Wang N, Wang X, Li W, Ye H, Bai H, Wu J, Chen M. Contrast-Enhanced CT Parameters of Gastric Adenocarcinoma: Can Radiomic Features Be Surrogate Biomarkers for HER2 Over-Expression Status? Cancer Manag Res 2020;12:1211-9. [PMID: 32110095 DOI: 10.2147/CMAR.S230138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhao H, Li W, Huang W, Yang Y, Shen W, Liang P, Gao J. Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer. AJR Am J Roentgenol 2021;216:1539-48. [PMID: 33852330 DOI: 10.2214/AJR.20.23528] [Reference Citation Analysis]
8 Grieb BC, Agarwal R. HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Curr Treat Options Oncol 2021;22:88. [PMID: 34424404 DOI: 10.1007/s11864-021-00884-7] [Reference Citation Analysis]
9 Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limón ML, Sauri T, López F, Visa L, Granja M, Martínez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martín Carnicero A, Mangas M, Pimentel P, Fernández Montes A, Macias Declara I, Longo F, Ramchandani A, Martín Richard M, Hurtado A, Azkarate A, Hernández Pérez C, Serrano R, Gallego J; AGAMENON-SEOM study group. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol 2021;13:17588359211019672. [PMID: 34211587 DOI: 10.1177/17588359211019672] [Reference Citation Analysis]
10 Ding X, Ding J. Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report. Mol Clin Oncol 2021;15:151. [PMID: 34141430 DOI: 10.3892/mco.2021.2313] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mitani S, Kawakami H. Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers (Basel) 2020;12:E400. [PMID: 32050652 DOI: 10.3390/cancers12020400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
12 Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, Ajani JA. Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). J Clin Oncol 2021;39:990-1000. [PMID: 33577358 DOI: 10.1200/JCO.20.02755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Pucher PH, Allum WH, Bateman AC, Green M, Maynard N, Novelli M, Petty R, Underwood TJ, Gossage J. Consensus recommendations for the standardized histopathological evaluation and reporting after radical oesophago-gastrectomy (HERO consensus). Dis Esophagus 2021:doab033. [PMID: 33969411 DOI: 10.1093/dote/doab033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188549. [PMID: 33894300 DOI: 10.1016/j.bbcan.2021.188549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Roviello G, Aprile G, D'Angelo A, Iannone LF, Roviello F, Polom K, Mini E, Catalano M. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? Gastric Cancer 2021;24:765-79. [PMID: 33742317 DOI: 10.1007/s10120-021-01182-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer 2020;19:156-64. [PMID: 32513593 DOI: 10.1016/j.clcc.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
17 Catenacci DVT, Chung HC, Shen L, Moehler M, Yoon HH, Rosales MK, Kang YK. Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open 2021;7:100360. [PMID: 34973512 DOI: 10.1016/j.esmoop.2021.100360] [Reference Citation Analysis]